Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seagen To Surge Ahead As ADCs Become Frontline Cancer Therapies

Padcev Plus Keytruda To Become Bladder Cancer Blockbuster

Executive Summary

Putting its CEO crisis and takeover rumors behind it, Seagen has big plans to expand its leading position in antibody-drug conjugates in 2023.

You may also be interested in...



Seagen’s Tukysa Trial With Kadcyla Supports ADC Combination, But Safety Paramount

Results of the HER2CLIMB-02 study supported Tukysa combinations with antibody-drug conjugates. However, treatment discontinuations drew caution.

Pfizer-gen? Pfizer Is The Latest Rumored Suitor For Seagen

Pfizer and Seagen reportedly are in merger discussions, signaling Pfizer’s willingness to invest significantly in antibody-drug conjugates (ADCs) for cancer.

Seagen Digs Deep For Lava’s Bispecific Antibody

Deal Snapshot: The Dutch biotech planned to move its preclinical candidate, the EGFR-targeting LAVA-1223, into the clinic later this year. Seagen has shown interest in business development as Merck merger talks have quieted down.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel